Revisi per 17 Mei 2024 08.55 sunting WanaraLima (bicara \| kontrib) 1.730 suntingan Artikel baru tentang topik farmasi yang masih memerlukan tambahan dan pengembangan Tag: VisualEditor ← Revisi sebelumnya		Revisi per 17 Mei 2024 09.10 sunting balikkan Mr. Ibrahem (bicara \| kontrib) 49 suntingan Fix references, Expend infobox mdwiki.toolforge.org. Revisi selanjutnya →
Baris 11: <!-- Chemical and physical data -->\|C=23\|Cl=1\|H=23\|N=6\|O=2\|smiles=C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl\|StdInChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1\|StdInChI_Ref={{stdinchicite\|changed\|chemspider}}\|StdInChIKey=JYTNQNCOQXFQPK-MRXNPFEDSA-N\|StdInChIKey_Ref={{stdinchicite\|changed\|chemspider}}}} '''Suvorexant''' adalah [[obat]] yang digunakan untuk mengatasi [[insomnia]], juga untuk mengatasi kondisi sulit tidur dan kondisi tetap tertidur. <ref name="AHFS2021">{{Cite web\|title=Suvorexant Monograph for Professionals \|url=https://www.drugs.com/monograph/suvorexant.html \|website=Drugs.com \|language=en \|archive-date=7 March 2016 \|archive-url=https://web.archive.org/web/20160307083716/http://www.drugs.com/monograph/suvorexant.html \|url-status=live \|access-date=15 October 2021}}</ref> Penggunaan obat ini mungkin efektif setidaknya selama satu tahun. <ref name="AHFS2021"~~>{{cite~~ ~~web \|title=Suvorexant Monograph for Professionals \|url=https:~~//www.drugs.com/monograph/suvorexant.html \|website=Drugs.com \|accessdate=15 October 2021 \|language=en \|archive-date=7 March 2016 \|archive-url=https://web.archive.org/web/20160307083716/http://www.drugs.com/monograph/suvorexant.html \|url-status=live }}</ref> Aturan minum obat ini melalui oral, dan diminum setengah jam sebelum tidur. <ref name="AHFS2021"~~>{{cite~~ ~~web \|title=Suvorexant Monograph for Professionals \|url=https:~~//www.drugs.com/monograph/suvorexant.html \|website=Drugs.com \|accessdate=15 October 2021 \|language=en \|archive-date=7 March 2016 \|archive-url=https://web.archive.org/web/20160307083716/http://www.drugs.com/monograph/suvorexant.html \|url-status=live }}</ref> Efek samping yang umum terjadi muncul rasa kantuk, sakit kepala, batuk, bermimpi, dan mulut kering. <ref name="AHFS2021"~~>{{Cite~~ ~~web\|title=Suvorexant Monograph for Professionals \|url=https:~~//www.drugs.com/monograph/suvorexant.html \|website=Drugs.com \|language=en \|archive-date=7 March 2016 \|archive-url=https://web.archive.org/web/20160307083716/http://www.drugs.com/monograph/suvorexant.html \|url-status=live \|access-date=15 October 2021}}<cite class="citation web cs1" data-ve-ignore="true">[https://www.drugs.com/monograph/suvorexant.html "Suvorexant Monograph for Professionals"]. ''Drugs.com''. [https://web.archive.org/web/20160307083716/http://www.drugs.com/monograph/suvorexant.html Archived] from the original on 7 March 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">15 October</span> 2021</span>.</cite></ref> Efek samping lainnya yang perlu diperhatikan secara serius yakni: [[kelumpuhan tidur]], muncul rasa ingin [[bunuh diri]], rasa cemas, dan menurunnya kemampuan mengemudi. <ref name="AHFS2021"~~>{{cite~~ ~~web \|title=Suvorexant Monograph for Professionals \|url=https:~~//www.drugs.com/monograph/suvorexant.html \|website=Drugs.com \|accessdate=15 October 2021 \|language=en \|archive-date=7 March 2016 \|archive-url=https://web.archive.org/web/20160307083716/http://www.drugs.com/monograph/suvorexant.html \|url-status=live }}</ref> Penggunaan pada ibu hamil dan menyusui masih belum diketahui secara jelas. <ref>{{Cite web\|title=Suvorexant (Belsomra) Use During Pregnancy\|url=https://www.drugs.com/pregnancy/suvorexant.html\|website=Drugs.com\|language=en\|archive-url=https://web.archive.org/web/20210124004709/https://www.drugs.com/pregnancy/suvorexant.html\|archive-date=24 January 2021\|access-date=15 October 2021\|url-status=live}}</ref> Obat ini merupakan [[antagonis reseptor]] orexin ganda (DORA). <ref name="AHFS2021"~~>{{cite~~ ~~web \|title=Suvorexant Monograph for Professionals \|url=https:~~//www.drugs.com/monograph/suvorexant.html \|website=Drugs.com \|accessdate=15 October 2021 \|language=en \|archive-date=7 March 2016 \|archive-url=https://web.archive.org/web/20160307083716/http://www.drugs.com/monograph/suvorexant.html \|url-status=live }}</ref> Penggunaan obat suvorexant telah disetujui untuk medis di Amerika Serikat pada tahun 2014, <ref name="AHFS2021"~~>{{Cite~~ web\|title=Suvorexant Monograph for Professionals \|url=https://www.drugs.com/monograph/suvorexant.html \|website=Drugs.com \|language=en \|archive-date=7 March 2016 \|archive-url=https://web.archive.org/web/20160307083716/http://www.drugs.com/monograph/suvorexant.html \|url-status=live \|access-date=15 October 2021}}<cite class="citation web cs1" data-ve-ignore="true">[https://www.drugs.com/monograph/suvorexant.html "Suvorexant Monograph for Professionals"]. ''Drugs.com''. [https://web.archive.org/web/20160307083716/http://www.drugs.com/monograph/suvorexant.html Archived] from the original on 7 March 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">15 October</span> 2021</span>.</cite></~~ref~~> dan untuk Kanada baru tahun 2018. <ref>{{Cite web\|title=Regulatory Decision Summary - Belsomra - Health Canada\|url=https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00475\|website=hpr-rps.hres.ca\|publisher=Government of Canada\|archive-url=https://web.archive.org/web/20200706141254/https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00475\|archive-date=6 July 2020\|access-date=6 February 2020\|url-status=live}}</ref> == Referensi ==

Suvorexant: Perbedaan antara revisi